Sutter Health Research Enterprise
11795 Education Street
Suite 232
Auburn, CA, 95602
(888) 729-3488
kimbk@sutterhealth.org
Related Clinical Trials
Adjuvant Breast (EndoPredict Extended Endocrine Trial EXET Myriad)
To evaluate the impact of using EndoPredict clinically to inform treatment decisions for extended endocrine therapy and the subsequent impact on patient outcome
Investigators: Kristin N. Arreola M.D., Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Jaspreet K Dhillon Medical Oncologist, Brian K. Kim M.D, Sivakumar Reddy M.D., Nitin Rohatgi MD, Vijay Suhag M.D.
Status: Active, Recruiting
City of Hope 96144 Molecular Genetics Studies of Cancer Patients and Their Relatives
The purpose of this study is to find out how genetics, biologics and behavior might contribute to
Investigators: Kristin N. Arreola M.D., Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Brian K. Kim M.D, Sivakumar Reddy M.D., Vijay Suhag M.D.
Status: Active, Recruiting
Imaging of T-cell Activation With [18F]F-AraG in Advanced NSCLC
Pilot study using [18F]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC
Investigators: Deepti Behl MD, Brian K. Kim M.D, Vijay Suhag M.D.
Status: Active, Recruiting
Locally Advanced (TIGeR-PaC Study)
Multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Investigators: Deepti Behl MD, Brian K. Kim M.D, Christopher J Laing M.D., Sivakumar Reddy M.D., Vijay Suhag M.D.
Status: Active, Recruiting
Metastatic (AstraZeneca D533AC00001 MONETTE)
AstraZeneca D533AC00001 MONETTE: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresect
Investigators: Kristin N. Arreola M.D., Deepti Behl MD, Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Jaspreet K Dhillon Medical Oncologist, Dron Gauchan MD, Brian K. Kim M.D, Sivakumar Reddy M.D., Vijay Suhag M.D.
Status: Active, Not Recruiting
Research Studies
Adjuvant (Guardant Health 02-MX-003 ORACLE)
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE)
Investigators: Kristin N. Arreola M.D., Deepti Behl MD, Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Jaspreet K Dhillon Medical Oncologist, Brian K. Kim M.D, Sivakumar Reddy M.D., Vijay Suhag M.D.